SCHEMBL5498846

SCHEMBL5498846

CC1=CC(C)(C)Nc2c(C)ccc(F)c21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 17/20 0.43
▸ NR3C1 P04150 4/20 0.38
▸ AR P10275 4/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ ESR1 P03372 1/20 0.36
▸ NR3C2 P08235 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5495793 0.85 ALDH1A1 (0.41) PGRALDH1A1HSD17B10KDM4EHPGD
SCHEMBL4193038 0.79 CES1 (0.46) PGRNR3C1ARALDH1A1HSD17B10
SCHEMBL4196337 0.75 PGR (0.39) PGRNR3C1ARALDH1A1HSD17B10
SCHEMBL27704548 0.72 PGR (0.44) PGRNR3C1ARALDH1A1HSD17B10
SCHEMBL5501394 0.70 ACHE (0.40) PGRNR3C1ALDH1A1HSD17B10KDM4E
SCHEMBL5506049 0.68 PGR (0.44) PGRNR3C1ARALDH1A1HSD17B10
SCHEMBL5504997 0.67 ELANE (0.37) PGRNR3C1ALDH1A1HSD17B10KDM4E
SCHEMBL10841208 0.67 ALDH1A1 (0.47) PGRARALDH1A1HSD17B10KDM4E
SCHEMBL8024917 0.67 ALDH1A1 (0.56) PGRARALDH1A1HSD17B10KDM4E
SCHEMBL5508770 0.65 ALDH1A1 (0.38) PGRNR3C1ARALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 — — US disclosed
CN-101018552-A Intracellular receptor modulator compounds and methods LIGAND PHARM INC (US) 2007-08-15 — — CN disclosed
EP-1778233-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2007-05-02 — — EP disclosed
WO-2006019716-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 PGR 953/4885NR3C1 533/4885AR 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback